Nomura Asset Management Co. Ltd. Sells 9,958 Shares of IDEXX Laboratories, Inc. $IDXX

Nomura Asset Management Co. Ltd. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,144 shares of the company’s stock after selling 9,958 shares during the period. Nomura Asset Management Co. Ltd. owned about 0.05% of IDEXX Laboratories worth $29,188,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter worth about $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories in the second quarter valued at approximately $30,000. Greykasell Wealth Strategies Inc. bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $36,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research analyst reports. BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $566.79 on Tuesday. The firm has a market cap of $44.71 billion, a P/E ratio of 41.74, a price-to-earnings-growth ratio of 3.27 and a beta of 1.56. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1-year low of $504.56 and a 1-year high of $769.98. The business’s 50 day moving average is $564.32 and its 200-day moving average is $635.65.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.